Literature DB >> 18349168

Guillain-Barré syndrome in a patient receiving anti-tumour necrosis factor alpha for rheumatoid arthritis: a case report and discussion of literature.

S Silburn, E McIvor, A McEntegart, H Wilson.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18349168     DOI: 10.1136/ard.2005.043208

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  6 in total

Review 1.  Imaging spectrum of immunomodulating, chemotherapeutic and radiation therapy-related intracranial effects.

Authors:  Christie M Lincoln; Peter Fata; Susan Sotardi; Michael Pohlen; Tomas Uribe; Jacqueline A Bello
Journal:  Br J Radiol       Date:  2017-11-03       Impact factor: 3.039

Review 2.  Adverse reactions to biologic agents and their medical management.

Authors:  Onur Boyman; Denis Comte; François Spertini
Journal:  Nat Rev Rheumatol       Date:  2014-08-12       Impact factor: 20.543

Review 3.  Severe Guillain-Barré syndrome in a patient receiving anti-TNF therapy. Consequence or coincidence. A case-based review.

Authors:  Bonifacio Alvarez-Lario; Rosa Prieto-Tejedo; María Colazo-Burlato; Jesús Macarrón-Vicente
Journal:  Clin Rheumatol       Date:  2013-05-11       Impact factor: 2.980

4.  Acute bilateral vision deficit as the initial symptom in Guillain-Barre syndrome: A case report.

Authors:  Hui-Jun Wen
Journal:  Exp Ther Med       Date:  2018-07-18       Impact factor: 2.447

5.  Ulcerative colitis with Guillain-Barré syndrome: A case report.

Authors:  Zhengru Liu; Ke Zhou; Shan Tian; Weiguo Dong
Journal:  Medicine (Baltimore)       Date:  2018-06       Impact factor: 1.889

6.  Concomitant Guillain-Barré Syndrome in a young Sri Lankan male with severe ulcerative colitis.

Authors:  Jayasundara Mudiyanselage Hishali Dahami Jayasundara; Vajira Tharanga Samarawickrama; Ranjith Peiris; Tilan Aponso; Danushi Abeynayake
Journal:  BMC Gastroenterol       Date:  2022-09-05       Impact factor: 2.847

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.